Enliven Therapeutics (ELVN) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Enliven Therapeutics (ELVN) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 113.9% versus a loss of 1.3%. Over five years, ELVN leads with a +254.6% price change compared with +63.7% for VRDN. Enliven Therapeutics is the larger company by market cap ($3.42 billion vs $3.40 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELVN | VRDN |
|---|---|---|
| Share price | $46.53 | $29.96 |
| Market cap | $3.42B | $3.40B |
| 1-day change | +0.26% | -4.71% |
| YTD return | +202.14% | -3.73% |
| 1-year return | +113.93% | -1.25% |
| 5-year return | +254.65% | +63.72% |
| EPS (TTM) | $-1.69 | $-3.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $70.85M |
| Revenue growth (YoY) | — | +23359.93% |
| Net income (latest FY) | $-103.69M | $-342.60M |
| Operating margin | — | -512.91% |
| Net margin | — | -483.57% |
| 52-week high | $62.32 | $34.29 |
| 52-week low | $14.79 | $13.18 |
| Distance from 52-week high | -25.34% | -12.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +59.75% | +42.72% |
| Average volume | 1.36M | 2.14M |
| Shares outstanding | 73.60M | 113.56M |
| Employees | 65 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELVN has outperformed VRDN by 115.2 percentage points over the past year.
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
ELVN vs VRDN FAQ
Which is bigger, Enliven Therapeutics or Viridian Therapeutics?
Enliven Therapeutics (ELVN) is larger, with a market capitalization of $3.42B compared with $3.40B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, ELVN or VRDN?
ELVN returned +113.93% over the past 12 months, compared with -1.25% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Enliven Therapeutics and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.